Best Practice No 181: Chemical pathology clinical investigation and management of nephrolithiasis

Journal of Clinical Pathology

Volumn 58, Issue 2, 2005, Pages 134-140

  Reynolds, T M ^a  

^a QUEEN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; ASCORBIC ACID; BENDROFLUMETHIAZIDE; BICARBONATE; BUCILLAMINE; CALCIUM; CHELATING AGENT; CHLOROTHIAZIDE; CHLORTALIDONE; CITRATE POTASSIUM; CITRIC ACID; CYSTOPURIN; ESSENTIAL FATTY ACID; GLYCEROPHOSPHATE MAGNESIUM; HYDROCHLOROTHIAZIDE; INDAPAMIDE; MAGNESIUM; MAGNESIUM HYDROXIDE; OXALIC ACID; PENICILLAMINE; POTASSIUM; PROTEIN; PURINE; PYRIDOXINE; SODIUM; THIAZIDE DIURETIC AGENT; TIOPRONIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; URATE; VITAMIN; OXALIC ACID DERIVATIVE; URIC ACID;

ALKALINIZATION; ARTHRALGIA; BLOATING; CALCIUM INTAKE; CALCIUM URINE LEVEL; CLINICAL TRIAL; COLIC; CYSTINE STONE; DENT DISEASE; DIARRHEA; DIET RESTRICTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; ENTERITIS; FLUID INTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPEROXALURIA; HYPERURICOSURIA; HYPOCITRATURIA; HYPOMAGNESEMIA; LABORATORY TEST; LEUKOPENIA; LOOSE BOWEL; METABOLIC DISORDER; NEPHRITIS; NEPHROLITHIASIS; NONHUMAN; PATHOLOGY; POTASSIUM INTAKE; PRIORITY JOURNAL; PROTEIN RESTRICTION; PROTEINURIA; RECURRENT INFECTION; REVIEW; SIDE EFFECT; SODIUM RESTRICTION; STONE ANALYSIS; THROMBOCYTOPENIA; URIC ACID STONE; URINALYSIS; URINE ALKALINIZATION; URINE PH; VITAMIN INTAKE; X CHROMOSOME LINKED DISORDER; BLOOD; CHEMISTRY; CYSTINURIA; KIDNEY TUBULE ACIDOSIS; METHODOLOGY; URINE;

ACIDOSIS, RENAL TUBULAR; CALCIUM; CALCIUM, DIETARY; CITRATES; CYSTINURIA; DIET, PROTEIN-RESTRICTED; HUMANS; INFLAMMATORY BOWEL DISEASES; KIDNEY CALCULI; OXALATES; URIC ACID; URINALYSIS;

EID: 13244298513     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2004.019588     Document Type: Review

References (82)

1. Bihl G, Meyers A. Recurrent renal stone disease-advances in pathogenesis and clinical management. Lancet 2001;358:651-6.
2. Wilkinson H. Clinical investigation and management of patients with renal stones. Ann Clin Biochem 2001;38:180-7.
3. Pantonowitz D, Pollen J, Politzer WM. Urinary calculi. S Afr Med J 1973;43:128-31.
4. Meyers AM, Whalley N, Martins M. Diagnostic and therapeutic aspects of recurrent renal stones disease. African Journal of Neprology 1998;2:12-17.
5. Daudon M, Donsimoni R, Hennequin C, et al. Sex- and age-related composition of 10617 calculi analysed by infrared spectroscopy. Urol Res 1995;23:319-26.
6. Bushinsky DA. Kidney stones. Adv Intern Med 2001;47:219-38.
7. Ozkaya O, Soylemezoglu O, Misirlioglu M, et al. Polymorphisms in the vitamin D receptor gene and the risk of calcium nephrolithiasis in children. Eur Urol 2003;44:150-4.
8. Mossetti G, Vuotto P, Rendina D, et al. Association between vitamin D receptor gene polymorphisms and tubular citrate handling in calcium nephrolithiasis. J Intern Med 2003;253:194-200.
9. Vezzoli G, Soldati L, Proverbio MC, et al. Polymorphism of vitamin D receptor gene start codon in patients with calcium kidney stones. J Nephrol 2002;15:158-64.
10. Heilberg IP, Teixeira SH, Martini LA, et al. Vitamin D receptor gene polymorphism and bone mineral density in hypercalciuric calcium-stone-forming patients. Nephron 2002;90:51-7.
11. Vezzoli G, Tanini A, Ferrucci L, et al. Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients. J Am Soc Nephrol 2002;13:2517-23.
12. Tiselius HG, Ackerman D, Alken P, et al. EAU guidelines: guidelines on urolithiasis. Eur Urol 2001;40:362-71.
13. Tiselius H-G. Medical evaluation of nephrolithiasis. Endocrinol Metab Clin North Am 2002;31:1031-50.
14. Norden AG, Scheinman SJ, Deschodt-Lanckman MM, et al. Tubular proteinuria defined by a study of Dent's (CLCN5 mutation) and other tubular diseases. Kidney Int 2000;57:240-9.
15. Whalley N, Martins MC, Wandy KRC, et al. Lithogenic risk factors in normal black volunteers, and black and white recurrent stone formers. BJU Int 1999;84:243-8.
16. Worcester EM. Inhibitors of stone formation. Semin Nephrol 1996;16:474-86.
17. Smith CL. Renal stone analysis: is there any clinical value? Curr Opin Nephrol Hypertens 1998;7:703-9.
18. Robertson WG, Peacock M. Calcium crystalluria in recurrent renal stone formers. Lancet 1969;2:21-4.
19. Randall A. Papillary pathology as a precursor of primary renal calculus. J Urol 1940;44:580-9.
20. Henderson MJ. Stone analysis is not useful in the routine investigation of renal stone disease. Ann Clin Biochem 1995;32:109-11.
21. Kasidas GP, Samuell CT, Weir TB. Renal stone analysis: why and how? Ann Clin Biochem 2004;41:91-7.
22. Hoskins DH, Erickson SB, Vandenburg Q. The stone clinic effect in patients with idiopathic calcium urolithiasis. J Urol 1983;130:1115-18.
23. Borghi L, Meschi T, Schianchi T, et al. Urine volume: stone risk factor and preventive measure. Nephron 1999;81(suppl):31-7.
24. Skov AR, Toubro S, Bulow J, et al. Changes in renal function during weight loss induced by high vs. low-protein low-fat diets in overweight subjects. Int J Obes Relat Metab Disorder 1999;23:1170-7.
25. Colina VL, Perez-Gonzalez M, Villalobos J, et al. Effect of hypoproteic diets enriched with essential and non-essential amino acids on the uninephrectomised rat. Acta Cient Venez 2002;53:21-8.
26. Martini LA, Heilberg IP. Stop dietary calcium restriction in kidney stone-forming patients. Nutr Rev 2002;60:212-14.
27. Iguchi M, Kataoka K, Kohri K, et al. Nutritional risk factors in calcium stone disease in Japan. Urol Int 1984;39:32-5.
28. Heller HJ. The role of calcium in the prevention of kidney stones. J Am Coll Nutr 1999;18:373S-8S.
29. Messa P, Marangella M, Paganin L, et al. Different dietary calcium intake and relative supersaturafion of calcium oxalate in the urine of patients forming renal stones. Clin Sci 1997;93:257-63.
30. Robertson WG, Hughes H. Importance of mild hyperoxaluria in the pathogenesis of urolithiasis: new evidence from studies in the Arabian peninsula. Scanning Microsc 1993;7:391-4.
31. Curhan GC, Willett WC, Rimm EB, et al. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993;328:833-8.
32. Curhan GC, Willett WC, Speizer FE, et al. Comparison of dietary calcium with supplementary calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997;126:497-504.
33. Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent renal stones in idiopathic hypercalciuria. N Engl J Med 2002;346:77-84.
34. Hess B. Low calcium diet in hypercalciuria calcium nephrolithiasis patients: first do no harm. Scanning Microsc 1996;10:547-54.
35. Brinkley LJ, Gregory J, Pak CYC. A further study of oxalate bioavailability in foods. J Urol 1990;144:94-6.
36. Worcester EM. Stones from bowel disease. Endocrinol Metab Clin North Am 2002;31:979-99.
37. Borghi L, Meschi T, Schianchi T, et al. Medical treatment of nephrolithiasis. Endocrinol Metab Clin North Am 2002;31:1051-64.
38. Savage GP, Charrier MJ, Vanhanen L. Bioavailability of soluble oxalate from tea and the effect of consuming milk with the tea. Eur J Clin Nutr 2003;57:415-19.
39. Hess B, Jost C, Zipperle L, et al. High calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. Nephrol Dial Transplant 1998;13:2241-7.
40. Heath D, Slocum MS, Clapp TG. Addressing salt issues in textile dyeing using an ISQ and ARIZ. http://www.tri2-journal.com/archives/2000/01/d/ (last accessed 02/02/04).
41. Lemann J, Adams ND, Gray RW. Urinary calcium excretion in human beings. N Engl J Med 1979;301:535-41.
42. Lemann J, Pleuss JA, Gray RW, et al. Potassium administration reduces and potassium deprivation increases urinary calcium excretion in healthy adults. Kidney Int 1991;39:973-83.
43. Borsatti A. Calcium oxalate nephrolithiasis: defective oxalate transport. Kidney Int 1991;39:1283-98.
44. http://www.foodstandards.gov.uk/healthiereating/dailydiet/salt/ (last accessed 02/01/04).
45. Shekarriz B, Stoller M. Uric acid nephrolithiasis: current concepts and controversies. J Urol 2002;168:1307-14.
46. Hess B. Nutritional aspects of stone disease. Endocrinol Metab Clin North Am 2002;31:1017-30.
47. Sorensen CM, Chandhoke PS. Hyperuricosuric calcium nephrolithiasis. Endocrinol Metab Clin North Am 2002;31:915-25.
48. Hughes C, Dutton S, Trusell A. High intakes of ascorbic acid and urinary oxalate. J Hum Nutr 1981;35:272-80.
49. Wandzilak T, D'Andre S, Davis P, et al. Effect of high dose of vitamin C on urinary oxalate levels. J Urol 1994;151:834-7.
50. Curhan GC, Willett WC, Speizer FE, et al. Intake of vitamin B6 and C and the risk of kidney stones in women. J Am Soc Nephrol 1999;10:840-5.
51. Burgess NA, Reynolds TM, Williams N, et al. Evaluation of four animal models of intrarenal calcium deposition and assessment of the influence of dietary supplementation with essential fatty acids on calcification. Urol Res 1995;23:239-42.
52. Baggio B. Genetic and dietary factors in idiopathic calcium nephrolithiasis. What do we have, what do we need? J Nephrol 1999;12:371-4.
53. Pearle MS. Prevention of nephrolithiasis. Curr Opin Nephrol Hypertens 2001;10:203-9.
54. Ackermann DK. Prospective therapeutic studies in nephrolithiasis. World J Urol 1997;15:172-5.
55. Pearle MS, Roehrborn CG, Pak CY. Meta-analysis of randomised trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol 1999;13:079-85.
56. Asplin JR. Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am 2002;31:927-49.
57. Gurhan GC, Willett WC, Speizer FE, et al. Intake of vitamins B6 and C and the risk of kidney stones in women. J Am Soc Nephrol 1999;10:840-5.
58. Ettinger B, Tang A, Citron JT, et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986;27:1386-9.
59. Pak CYC. Medical prevention of renal stone disease. Nephron 1999;81(suppl):60-5.
60. Pak CYC. Citrate and renal calculi: an update. Miner Electrolyte Metab 1994;20:371-7.
61. Barcelo P, Wuhl O, Servitge E, et al. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 1993;150:1761-4.
62. Ettinger B, Pak CYC, Citron JT, et al. Potassium-magnesium citrate is on effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 1997;158:2009-73.
63. Zerwech JE, Reed-Gitomer BY, Pak CYC. Pathogenesis of hypercalciuric nephrolithiasis. Endocrinol Metab Clin North Am 2002;31:869-84.
64. Reynolds T, Burgess N, Matanhelia S, et al. The frusemide test: a simple screening test for urinary acidification defect in urolithiasis. Br J Urol 1993;72:153-6.
65. Wollaston WH. On cystic oxide: a new species of urinary calculus. Transactions of the Royal Society London 1810;100:223-30.
66. Shekarriz B, Stoller ML. Cystinuria and other noncalcareous calculi. Endocrinol Metab Clin North Am 2002;31:951-77.
67. Calonge MJ, Gasporini P, Chillaron J, et al. Cystinuria caused by mutations in rBAT, a gene involved in the transport of cystine. Nat Genet 1994;6:420-5.
68. Guillen M, Corella D, Cabello ML, et al. Association between M467T and 114 C→A variants within the SLC3A1 gene and some phenotypical traits in cystinuria patients from Spain. Hum Genet 2000;106:314-20.
69. Preminger GM. Renal calculi: pathogenesis, diagnosis and medical therapy. Semin Nephrol 1992;12:200-16.
70. Wilson DM. Clinical and laboratory evaluation of renal stone patients. Endocriniol Metab Clin North Am 1990;19:773-803.
71. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992;327:1141-52.
72. Hodgman CD, Weast RC, Selby SM. Handbook of chemistry and physics, 40th ed. Cleveland Ohio: Chemical Rubber Publishing Co, 1958.
73. Milliner DS. Cystinuria. Endocrinol Metab Clin North Am 1990;19:889-907.
74. Abrahams HM, Stoller ML. Infection and urinary stones. Curr Opin Urol 2003;13:63-7.
75. Rodman JS. Struvite stones. Nephron 1999;81(suppl 1):50-9.
76. Scheinman JL. Primary hyperoxaluria: therapeutic strategies for the 90s. Kidney Int 1991;40:389-99.
77. Lumb MJ, Birdsey GM, Danpure CJ. Correction of an enzyme trafficking defect in hereditary kidney stone disease in vitro. Biochem J 2003;374:79-87.
78. Danpure CJ, Lumb LJ, Birdsey GM, et al. Alanine:glyoxalate aminotransferase peroxisome-to-mitochondrion mistargeting in human hereditary kidney stone disease. Biochim Biophys Acta 2003;1647:70-5.
79. Yendt ER, Cohanim M. Response to a physiologic dose of pyridoxine in type-1 hyperaxaluria. N Engl J Med 1985;315:1386-9.
80. Watts RWE, Morgan SH, Danpure CL, et al. Combined hepatic and renal transplantation in primary hyperoxaluria type-1: clinicai report of nine cases. Am J Med 1991;90:179-88.
81. Schieneman SJ. X-linked hypercalciuric nephrolithiasis: clinical syndromes and chloride channel mutations. Kidney Int 1998;53:3-17.
82. Heilberg IP. Update on recommendations and medical treatment of renal stone disease. Nephrol Dial Transpl 2000;15:117-23.